Reducing pathology in Alzheimer’s Disease through Angiotensin TaRgeting - The RADAR Trial

Lead Research Organisation: North Bristol Nhs Trust

Abstract

Alzheimer’s disease (AD) profoundly affects memory and brain function in older individuals. It is a slow progressive disease which can last for a number of years - a heart-breaking, exhausting and often costly reality for family and health services. With an ageing population, AD health care provision needs will significantly rise. Existing treatments only temporarily treat specific imbalances in the brain but as yet there is no cure for AD. We will undertake a clinical trial at Bristol (in collaboration with University College London (UCL)) to see if losartan, a well tolerated blood pressure drug, can complement current treatments for AD. We believe losartan will slow down the progression of AD by improving brain blood flow and altering chemical pathways that cause brain cell damage, brain shrinkage and memory problems in AD. This study will use brain imaging to measure if losartan reduces brain shrinkage which is already known to be strongly linked with reduced memory function. We will also investigate if losartan alters the profile and activity of various blood-borne proteins which may be predictive of rates of disease progression. We want to study losartan because human and animal studies tell us reduced brain blood flow is a very common and early feature in AD and contributes to memory failure. Losartan blocks a chemical pathway (angiotensin II) to improve memory problems in mice designed to have Alzheimer’s features and in people given chemicals to temporarily affect their memories. Losartan is thought to stop angiotensin II from preventing the release of vital memory chemicals in the brain. We recently found that people who have previously taken losartan, or similar drugs, have lower risk of developing AD compared to other blood pressure drugs. These drugs also slow the rate of deterioration in patients with Alzheimer’s. However clinical trials of losartan and related drugs in people with high blood pressure have shown little evidence of a reduced risk of cognitive decline or dementia in general. These studies however did not include or specifically identify AD patients and would have had many patients with mainly vascular dementia patients which have not benefited. There are no major ethical issues in this study. It may also appear costly for a small study, but it uses expensive surrogate markers of disease that can be studied in a shorter time. RADAR will offer great value for money if this cheap (3-4p per day) well tolerated drug is found to be beneficial in AD. RADAR will also provide the requisite evidence needed to justify the much larger multi-centre trial (which will use cheaper measures of disease over a longer study time) that will be needed to provide the final proof of losartan’s benefit in AD. This trial which involves leading international centres for angiotensin research in dementia (Bristol) and imaging (UCL) should provide such evidence.

Technical Summary

Research design: A two arm blinded placebo-controlled randomised controlled trial (RCT). Study population: RADAR will study incident and prevalent cases of mild-to-moderate AD diagnosed according to revised NINCDS-ADRDA criteria. Participants can be hypertensive or normotensive and on any existing dementia drugs with no age restrictions. Inclusion requires an MMSE score of 15-24; a modified Hachinski score of 4 or less, a previous CT or MRI scan supporting a diagnosis of AD and the presence of care-giver in daily contact. Exclusion criteria include anyone already taking other renin angiotensin acting drugs or potassium diuretics; contraindications or conditions that make MRI unfeasible; a BP of < 120/75 mmHg, > 160/110 mmHg and/or postural hypotension (BP drop of >20/10 mmHg after 3-5 minutes); prior history of stroke or transient ischaemic attacks; unstable congestive heart failure; severe renal or hepatic impairment or a history of gout; other primary neurodegenerative or psychiatric disorders other than AD or other possible primary causes of dementia; a recent history of untreated clinically significant hypothyroidism or hyperthyroidism (patients are euthyroid and stable are eligible). Interventions: Patients will be randomised to either encapsulated 100mg generic losartan or placebo once daily for 12 months after a 1 month open label phase which establish drug tolerability. Outcomes: Primary outcome measures will be the rate of whole brain atrophy as a surrogate measure of cognitive decline. Secondary outcomes: (i) white matter hyperintensities (WMH) volume and cerebral blood flow (CBF) (also surrogate markers of cognitive decline and disease progression); (ii) performance on a standard battery of assessments of memory, cognitive function, activities of daily living and quality of life; (iii) changes to levels of plasma protein markers of AD (Abeta, acetylcholinesterase) and AngII pathway-linked AD-related markers (ACE, NEP, TNFalpha, CRP). Major assessments (for all outcomes) will be at baseline and 12 months while an added interim 6 month visit will include cognitive assessments only. Safety monitoring for blood pressure and side effects will occur at weekly intervals of the open-label phase and at 14 days, 3, 6 and 9 months post-randomisation. Based on recent studies conducted within ADNI to optimise protocols for imaging use in clinical trials of AD, we will recruit a sample size of 228 participants (recruited over 15 months) to provide at least 182 subjects with final assessments to provide 84% power to detect a 25% difference in atrophy rate (therapeutic benefit) change over 12 months at an alpha level of 0.05. We will use intention-to-treat analysis to measure our outcomes, measuring between-group estimates of effectiveness derived from appropriate (linear or logistic) multivariable regression models adjusting for minimisation variables and value of outcome at baseline and at the end of the study (12 month follow-up for all primary and secondary outcomes) and for the 6 month cognitive assessment data.

Publications

10 25 50

 
Description MEMENTO Cognition Study in FRANCE
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
 
Description Age-associated changes in the renin-angiotensin system - implications for future clinical trials
Amount £84,274 (GBP)
Funding ID ARUK-PhD2018-012 
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2019 
End 12/2021
 
Description Age-associated changes in the renin-angiotensin system implications for future clinical trials.
Amount £83,000 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2019 
End 12/2022
 
Description Exploring the role of the renin-angotensin system in oxidative stress and mitochondrial dysfunction in Alzheimer's disease.
Amount £110,000 (GBP)
Organisation Government of Turkey 
Sector Public
Country Turkey
Start 10/2019 
End 09/2022
 
Description Overactivity of the brain renin-angiotensin system in cerebrovascular dysfunction and vascular cognitive impairment
Amount £264,343 (GBP)
Funding ID 395 
Organisation Alzheimer’s Society 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2018 
End 11/2021
 
Description Overactivity of the brain renin-angiotensin system in cerebrovascular dysfunction and vascular cognitive impairment.
Amount £264,343 (GBP)
Funding ID 395 
Organisation Alzheimer’s Society 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2018 
End 10/2021
 
Description Perros Trust PhD Scholarship
Amount £150,143 (GBP)
Organisation Perros Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2015 
End 08/2018
 
Description Proof of Concept Award
Amount $300,000 (USD)
Organisation BrightFocus Foundation 
Sector Charity/Non Profit
Country United States
Start 09/2016 
End 08/2019
 
Description University of Bristol Alumni
Amount £50,000 (GBP)
Organisation University of Bristol 
Sector Academic/University
Country United Kingdom
Start 03/2013 
End 03/2014
 
Title Power calculator for instrumental variable analysis in pharmacoepidemiology 
Description To address the need for dedicated power calculators for pharmacoepidemiological research. 
Type Of Material Physiological assessment or outcome measure 
Year Produced 2017 
Provided To Others? Yes  
Impact Possible use in subsequent publications but not my area of expertise. 
URL https://www.ncbi.nlm.nih.gov/pubmed/28575313
 
Title Using the MR-Base platform to investigate risk factors and drug targets for thousands of phenotypes 
Description "Describe how MR-Base can be used in several ways, including to perform novel causal analyses, replicate results and enable transparency, amongst others. We also present three use cases, which demonstrate important applications of Mendelian randomization and highlight the benefits of using MR-Base for these types of analyses." 
Type Of Material Physiological assessment or outcome measure 
Year Produced 2019 
Provided To Others? Yes  
Impact None known as yet 
URL https://www.ncbi.nlm.nih.gov/pubmed/31448343.2
 
Title RADAR Clinical Database 
Description This is a database developed for the collection and storage of data being collected over the course of the trial. It is intended to be accessible by all participating sites for the upload of data remotely to expedite data entry and collection for the study as a whole. 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact This system will enable data entry and collection across the multiple sites available in the RADAR Trial and provide a mechanism by which data can then be exported both for analysis in due course, for auditing purposes and for monitoring e.g. via DMEC for the trial. 
 
Description Bristol Dementia Pharmacoepidemiology Group 
Organisation Medicines and Healthcare Regulatory Agency
Department Clinical Practice Research Datalink (CPRD)
Country United Kingdom 
Sector Public 
PI Contribution I was a founding partner in a Bristol Medical School collective of researchers that investigates the possibility of drug repurposing of anti-hypertensive, statins and diabetes related medications for dementia. This included gaining funding for a PhD Studentship (now completed) that explored the anti-hypertensive medications side of things whilst the statin-based research is ongoing. My contributions were the generation of hypotheses and mechanistic interpretations of results.
Collaborator Contribution Epidemiological partners provided strong intellectual input into the analysis and methods to interrogate the CPRD data to answer the research questions posed.
Impact 10.1186/s13195-018-0379-6 10.1093/ije/dyz155 10.1136/bmjopen-2016-012044
Start Year 2011
 
Description Collaborative grant application 
Organisation Queen's University Belfast
Country United Kingdom 
Sector Academic/University 
PI Contribution An MRC DPFS application was submitted and re-invited subject to some changes.
Collaborator Contribution Led by colleagues in Belfast with specific expertise in retinal imaging that we can test its application in certain clinical trial approaches.
Impact None
Start Year 2014
 
Description Core Outcome Data Set for Dementia clinical trials (COD Dementia) 
Organisation University College London
Department Institute of Neurology
Country United Kingdom 
Sector Academic/University 
PI Contribution Resulting from a HTA/NIHR supported event this gave rise to an invitation from HTA to bid for a small amount of funds to come up with a set of 'consensus' outcome measures that could be applied to dementia clinical trials and an award was funded to the leads at UCL (HTA Project: 15/62/02).
Collaborator Contribution The first activity on this is scheduled for April 7th and is being co-ordinated by the UCL members who are the primary leads on this project - the initiative involves almost 40 collaborators.
Impact Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O'Brien JT, Mountain G, Banerjee S, Woods B, Perneczky R, Lafortune L, Roberts C, McCleery J, Pickett J, Bunn F, Challis D, Charlesworth G, Featherstone K, Fox C, Goodman C, Jones R, Lamb S, Moniz-Cook E, Schneider J, Shepperd S, Surr C, Thompson-Coon J, Ballard C, Brayne C, Burns A, Clare L,, Garrard P, Kehoe P, Passmore P, Holmes C, Maidment I, Robinson L, Livingston G. Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. PLoS One. 2017 Jun 29;12(6):e0179521. doi: 10.1371/journal.pone.0179521. eCollection 2017 Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O'Brien JT, Mountain G, Banerjee S, Woods B, Perneczky R, Lafortune L, Roberts C, McCleery J, Pickett J, Bunn F, Challis D, Charlesworth G, Featherstone K, Fox C, Goodman C, Jones R, Lamb S, Moniz-Cook E, Schneider J, Shepperd S, Surr C, Thompson-Coon J, Ballard C, Brayne C, Burke O, Burns A, Clare L, Garrard P, Kehoe P, Passmore P, Holmes C, Maidment I, Murtagh F, Robinson L, Livingston G. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technol Assess. 2017 May;21(26):1-192. doi: 10.3310/hta21260.
Start Year 2015
 
Description Health Evaluation in African Americans using RAS Therapy: The HEART Project. 
Organisation Emory University
Country United States 
Sector Academic/University 
PI Contribution I was invited to contribute to this study to evaluate the potential benefit of using a specific blood pressure drug, related to that in the RADAR Trial in relation to an ethnic minority group with a view to designing future studies for Alzheimer's disease and Mild Cognitive Impairment.
Collaborator Contribution The majority of the work was led in this in terms of protocol development and the funding application to the Alzheimer's Association in the US that I am listed as a collaborator on.
Impact Work just getting underway and protocol just been finalised.
Start Year 2015
 
Description Hypertension research in Dementia Group 
Organisation Emory University
Country United States 
Sector Academic/University 
PI Contribution Invited to provided expertise into a meta-analysis study of anti-hypertensive medications use and risk of dementia and cognitive decline that resulted in a publication in Neurology (https://n.neurology.org/content/94/3/e267.long) - i was responsible for the introduction of new research partners to the study to expand the data collection potential as well as contribute to the writing of the eventual publication.
Collaborator Contribution They initiated and led a meta-analysis study of anti-hypertensive medications use and risk of dementia and cognitive decline that resulted in a publication in Neurology (https://n.neurology.org/content/94/3/e267.long)
Impact http://(https://n.neurology.org/content/94/3/e267.long
Start Year 2016
 
Description Hypertension research in Dementia Group 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Invited to provided expertise into a meta-analysis study of anti-hypertensive medications use and risk of dementia and cognitive decline that resulted in a publication in Neurology (https://n.neurology.org/content/94/3/e267.long) - i was responsible for the introduction of new research partners to the study to expand the data collection potential as well as contribute to the writing of the eventual publication.
Collaborator Contribution They initiated and led a meta-analysis study of anti-hypertensive medications use and risk of dementia and cognitive decline that resulted in a publication in Neurology (https://n.neurology.org/content/94/3/e267.long)
Impact http://(https://n.neurology.org/content/94/3/e267.long
Start Year 2016
 
Description Hypertension research in Dementia Group 
Organisation Johns Hopkins Bayview Medical Center
Country United States 
Sector Hospitals 
PI Contribution Invited to provided expertise into a meta-analysis study of anti-hypertensive medications use and risk of dementia and cognitive decline that resulted in a publication in Neurology (https://n.neurology.org/content/94/3/e267.long) - i was responsible for the introduction of new research partners to the study to expand the data collection potential as well as contribute to the writing of the eventual publication.
Collaborator Contribution They initiated and led a meta-analysis study of anti-hypertensive medications use and risk of dementia and cognitive decline that resulted in a publication in Neurology (https://n.neurology.org/content/94/3/e267.long)
Impact http://(https://n.neurology.org/content/94/3/e267.long
Start Year 2016
 
Description RADAR trial 
Organisation Queen's University Belfast
Country United Kingdom 
Sector Academic/University 
PI Contribution This collaboration was formed off the back of various pre-clinical studies of brain tissue we have undertaken to culminate in a new award of £1.95 million
Collaborator Contribution These partners have served as co-applicants for the clinical trial that is now just about to commence.
Impact No outputs as yet - but received a grant of £1.94m for this multi-disciplinary (Neurology, Clinical Pharmacology, Mental Health) phase 2 trial.
Start Year 2013
 
Description RADAR trial 
Organisation University of Cambridge
Department School of Clinical Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution This collaboration was formed off the back of various pre-clinical studies of brain tissue we have undertaken to culminate in a new award of £1.95 million
Collaborator Contribution These partners have served as co-applicants for the clinical trial that is now just about to commence.
Impact No outputs as yet - but received a grant of £1.94m for this multi-disciplinary (Neurology, Clinical Pharmacology, Mental Health) phase 2 trial.
Start Year 2013
 
Description RASAD Trial Group 
Organisation Emory University
Department Emory School of Medicine
Country United States 
Sector Academic/University 
PI Contribution As a result of interactions and my experience on the RADAR trial I was invited to contribute to an NIH RO1 application (submitted and under-review) to undertake a new Phase II clinical trial of Aliskiren in Mild Cognitive Impairment.
Collaborator Contribution They have led the application to be undertaken at JHU and with Emory University and I serve as a Co-Investigator. All subject to successful funding.
Impact too early!
Start Year 2018
 
Description RASAD Trial Group 
Organisation Johns Hopkins University
Country United States 
Sector Academic/University 
PI Contribution As a result of interactions and my experience on the RADAR trial I was invited to contribute to an NIH RO1 application (submitted and under-review) to undertake a new Phase II clinical trial of Aliskiren in Mild Cognitive Impairment.
Collaborator Contribution They have led the application to be undertaken at JHU and with Emory University and I serve as a Co-Investigator. All subject to successful funding.
Impact too early!
Start Year 2018
 
Description US-UK Pharmacoepidemiology research in Dementia Group 
Organisation Arizona Department of Health Services
Country United States 
Sector Public 
PI Contribution I was invited to contribute to a large pharmacoepidemiological study of anti-hypertensive medication prescribing and use in a US prescription data set that has since been expanded into further studies of potential interactions with other classes of medications. I provided mechanistic insights into the hypotheses and interpretation of findings as well as contribute to eventual publications.
Collaborator Contribution The provided access to the source data and developed the statistical investigational protocols, undertook the analyses and lead on publications.
Impact 10.1371/journal.pone.0229541 10.1371/journal.pone.0206705
Start Year 2016
 
Description US-UK Pharmacoepidemiology research in Dementia Group 
Organisation Emory University
Country United States 
Sector Academic/University 
PI Contribution I was invited to contribute to a large pharmacoepidemiological study of anti-hypertensive medication prescribing and use in a US prescription data set that has since been expanded into further studies of potential interactions with other classes of medications. I provided mechanistic insights into the hypotheses and interpretation of findings as well as contribute to eventual publications.
Collaborator Contribution The provided access to the source data and developed the statistical investigational protocols, undertook the analyses and lead on publications.
Impact 10.1371/journal.pone.0229541 10.1371/journal.pone.0206705
Start Year 2016
 
Description US-UK Pharmacoepidemiology research in Dementia Group 
Organisation University of Southern California
Country United States 
Sector Academic/University 
PI Contribution I was invited to contribute to a large pharmacoepidemiological study of anti-hypertensive medication prescribing and use in a US prescription data set that has since been expanded into further studies of potential interactions with other classes of medications. I provided mechanistic insights into the hypotheses and interpretation of findings as well as contribute to eventual publications.
Collaborator Contribution The provided access to the source data and developed the statistical investigational protocols, undertook the analyses and lead on publications.
Impact 10.1371/journal.pone.0229541 10.1371/journal.pone.0206705
Start Year 2016
 
Description US-UK Pharmacoepidemiology research in Dementia Group 
Organisation University of Washington
Country United States 
Sector Academic/University 
PI Contribution I was invited to contribute to a large pharmacoepidemiological study of anti-hypertensive medication prescribing and use in a US prescription data set that has since been expanded into further studies of potential interactions with other classes of medications. I provided mechanistic insights into the hypotheses and interpretation of findings as well as contribute to eventual publications.
Collaborator Contribution The provided access to the source data and developed the statistical investigational protocols, undertook the analyses and lead on publications.
Impact 10.1371/journal.pone.0229541 10.1371/journal.pone.0206705
Start Year 2016
 
Title DIZE 
Description DIZE is an ACE2 enhancer compound, originally developed as a possible treatment for hypertension but which we are currently undertaking proof of concept work on with a view to its scope for repurposing in Alzheimer's disease. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Refinement. Non-clinical
Year Development Stage Completed 2017
Development Status Under active development/distribution
Impact If the proof of concept work is positive - then there will be scope to immediately test in humans, given that the compound has been available for a number of years to treat some difficult tropical diseases of the CNS. 
 
Description "Lift your memory by lowering your blood pressure: The Radar Trial" 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Attendees had the opportunity to meet with leading researchers from across the region and listen to 10-minute talks about their research projects.
Year(s) Of Engagement Activity 2015
URL http://www.eventbrite.co.uk/e/forgetwest-find-out-about-dementia-research-get-involved-west-of-engla...
 
Description Alzheimer's Research UK Public Lecture 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Between 80-150 people attend every year.
The speakers vary annually and represent the researchers local to the Centre.

There is an active mailing list who remain engaged and are returning year on year.
Year(s) Of Engagement Activity Pre-2006,2006,2007,2008,2009,2010,2011,2012,2013
 
Description Annual Health Sciences BSc lecture 2020 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Undergraduate students
Results and Impact 6 students on this years intake of the Bristol Medical School BSc in Health Sciences attended as part of their undergraduate studies.
Year(s) Of Engagement Activity 2020
 
Description Annual Intercalated BSc lecture 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Undergraduate students
Results and Impact Provided a lecture on the 2018 Batchelor of Health Sciences in my University for intercalating Medical Students.
Year(s) Of Engagement Activity 2018
 
Description Dementia HIT Clinical Research Showcase 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact An event showcase some of the portfolio of clinical dementia-related research going on in the greater Bristol area.
Year(s) Of Engagement Activity 2016
URL https://www.eventbrite.co.uk/e/dementia-hit-clinical-research-showcase-tickets-19378160600#
 
Description Invited Lecture to Vas-Cog 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A specialised session presenting new intervention strategies for diseases that include cerebrovascular dysfunction wherein my talk proposed new pathways and introduced our current study funded.
Year(s) Of Engagement Activity 2016
 
Description Invited Lecture to the Cardiff School of Pharmacy 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Undergraduate students
Results and Impact Introduction to new theories around molecular mechanisms of cerebrovascular disease as an introduction to the currently funded study.
Year(s) Of Engagement Activity 2017
 
Description Invited talk to Oakland University School of Medicine 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Gave an invitation talk about the scientific rationale for the RADAR trial and progress to-date.
Year(s) Of Engagement Activity 2018
 
Description Johns Hopkins University Lecture 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Gave an invitational lecture in which the study design and progress in the study was presented - resulted in me being invited to contribute to an NIH RO1 application, currently under review.
Year(s) Of Engagement Activity 2018
 
Description Plenary Lecture 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Stimulating discussion afterwards with a number of academics

Some new collaborations have been discussed.
Year(s) Of Engagement Activity 2014
 
Description Plenary Lecture at Trinity College Institute of Neuroscience 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Presentation to the Brain Research Institute, Trinity College Dublin discussing trial background and rationale.
Year(s) Of Engagement Activity 2017
 
Description Public lecture 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Had interested people seeking more information on the study

Was invited to join an outline application for another clinical trial in Alzheimer's disease.
Year(s) Of Engagement Activity 2014
URL http://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=2697
 
Description RADAR announcement across Scotland 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Press release put in place to coincide with the opening of a number of our Scottish partnering sites in Scotland opening to recruitment and as a means to direct queries to the sites in question.
Year(s) Of Engagement Activity 2015
URL http://www.bristol.ac.uk/news/2015/november/radar-trial.html
 
Description RADAR funding announcement radio Interview 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact A radio interview on BBC Bristol following the announcement of funding for the RADAR trial and it receiving front page news in National Newspapers.

We received a number of approaches from patients and carers requesting to participate in the trial.
Year(s) Of Engagement Activity 2013
 
Description RADIO Interviews in BBC Bristol & BBC Wilthshire 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Study participants or study members
Results and Impact Conducted a series of interviews to support the final phase of recruitment to recruit the final 100 participants needed to meet our targets in the trial. Interview scoped discussion about Alzheimer's disease, our study and what it is testing in the disease and how people could become involved.
Year(s) Of Engagement Activity 2017
URL https://www.bristol.ac.uk/news/2017/july/radar-trial.html
 
Description Results of the Reducing pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Platform presentation in the opening late-breaking communications session of the Clinical Trials in Alzheimer's Disease (CTAD) meeting 2019 in San Diego to an audience of ~800 to 1000 attendees
Year(s) Of Engagement Activity 2019
URL https://www.ctad-alzheimer.com/files/files/FINAL_PROGRAM_CTAD2019_au2oct%20final.pdf
 
Description South West recruitment boost 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Effort to announce the opening of additional recruitment sites in the region to help them get participants in and renew additional interest in previously opened sites that were mentioned again.
Year(s) Of Engagement Activity 2016
URL http://www.bristol.ac.uk/policybristol/news/2016/radar-trial-sw.html
 
Description The Reducing pathology in Alzheimer's Disease through Angiotensin taRgeting study (RADAR) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Platform Presentation at the 1st UK-Israel Dementia Prevention Conference in Tel Aviv, Israel
Year(s) Of Engagement Activity 2019
 
Description Together for dementia - Behind the headlines 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact "Together for Dementia" brought together people with diverse perspectives on dementia - researchers, clinicians, carers, care home managers, campaigners, designers, policy makers and, of course, people who themselves are living with dementia. Intended to provide a forum to help people learn about and discuss various aspects of dementia.
Year(s) Of Engagement Activity 2015
URL http://www.alzheimers-brace.org/events/brace-dementia-conference